Citations

Clear

3042 citation(s) found for "Kumar, S".

Abstract 1067: Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance
Voorhees, Peter, Sookiasian, Danielle , Hess, Julian M. , DeMeo, M.K., Pounder, Vicki, Calkins, Sarah, Meyer, Reid G., Baughn, Linda B., Liacos, Christine-Ivy, Dimopoulos, Meletios-Athanasios, Papadimou, Alexandra , Konstantina, Taouxi, Kastritis, Efstathios, Auclair, Daniel, Nardi, Valentina , Mullen, Thomas D., Kumar, Shaji Kunnathu, Paiva, Bruno , Voorhees, Peter M. , Greipp, Patricia T. , Baughn, Linda B. , Liacos, Christine‐Ivy , Dimopoulos, Meletios Α. , Taouxi, Konstantina , Kastritis, Efstathios , Berdeja, Jesús G. , Auclair, Daniel , Mullen, Thomas, Aguet, François

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1067-1067

10.1158/1538-7445.am2026-1067 Get It

Abstract The detection of genetic abnormalities is required during diagnostic workup and for potential individualization of therapy selection in multiple myeloma (MM) and its precursor conditions. At present, this relies on invasive bone marrow (BM) biopsies, severely limiting early detection, frequent longitudinal monitoring, and the precise selection of therapy. The current standard for detecting genetic alterations in MM is fluorescence in situ hybridization (FISH), which cannot detect point mutations and other clinically relevant alterations. Consequently, the IMS-IMWG guidelines were recently updated to require next-generation sequencing for the classification of high-risk MM. To address these needs, we recently launched GenoPredicta, a CLIA-approved LDT that enables routine monitoring, informing diagnosis, and treatment selection by comprehensively characterizing MM genomes with whole genome sequencing (WGS) from as few as 50 circulating tumor cells (CTCs) isolated from peripheral blood (PB) or tumor cells from BM. Briefly, tumor cells are isolated from samples using fluorescence-activated cell sorting and subjected to WGS, from which copy number alterations, structural variants, and short variants (SNVs/indels) are identified using a fully automated pipeline generating physician-ready clinical reports from raw sequencing data in ∼6h. Analytical validation of GenoPredicta showed complete concordance with FISH results. Identifying alterations in therapeutic targets (e.g., BCMA, GPRC5D) for guiding MM immunotherapies is becoming increasingly important. Here, we describe GenoPredicta results from relapsed/refractory MM patients, highlighting resistance-conferring alterations that can only be detected by WGS, such as deletions in the kilo- to megabase scales that are observed in conjunction with SNVs and indels, leading to biallelic loss/inactivation of the gene, including at subclonal levels. In addition to biallelic loss of BCMA and GPRC5D in response to CAR T or T cell engager therapies, we observed similar resistance mechanisms for targets of immunomodulatory drugs, e.g., CRBN. The observation of these resistance mechanisms was consistent with patients’ clinical histories. In summary, we demonstrate that low input WGS-based characterization of MM from BM or CTCs is a viable replacement for FISH for clinical diagnosis and monitoring, with CTC-based measurements enabling comprehensive profiling of the MM genome. Crucially, this includes genetic alterations that confer resistance to therapy, allowing for both early detection of such alterations and more precise selection and guidance of therapy. The dramatically improved variant calling ability from WGS, especially in low-input CTC applications, extends to other malignancies and will gain wider adoption as sequencing costs continue to decrease. Citation Format: Bruno Paiva, Peter Voorhees, Patricia T. Greipp, Danielle Sookiasian, Julian Hess, Marisa DeMeo, Vicki Pounder, Sarah Calkins, Reid Meyer, Linda B. Baughn, Christine-Ivy Liacos, Meletios-Athanasios Dimopoulos, Alexandra Papadimou, Taouxi Konstantina, Efstathios Kastritis, Jesus Berdeja, Daniel Auclair, Valentina Nardi, Thomas Mullen, Francois Aguet, Shaji Kunnathu Kumar. Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1067.
Antibody–Drug Conjugates in Gastrointestinal Oncology: Clinical Efficacy and Inpatient Toxicity Management
Sharma, Ashish , Kumar, Harendra , Paladiya, Ruchir, Sisodia, Rajvardhan , Alsakarneh, Saqr, Hayat, Umar, Sonaiya, Sneh , Pinnam, Hema Sameera, Ali, Hassam, Dahiya, Dushyant Singh , Ali, Hassam , Kumar, Harendra , Pinnam, Hema Sameera , Dahiya, Dushyant Singh , Bharadwaj, Hareesha Rishab , Mohamed, Islam

Mayo Clinic

Journal of Personalized Medicine | April 1, 2026 | Volume: 16 | Issue: 4 | Pages: 195

10.3390/jpm16040195 | PMID 42042562 Get It

Antibody–drug conjugates (ADCs) are reshaping the therapeutic approach to advanced gastrointestinal cancers by integrating tumor-specific monoclonal antibodies with potent cytotoxic payloads to improve targeted tumor cell destruction while minimizing systemic exposure. Compared to traditional chemotherapy, trastuzumab deruxtecan has significantly improved objective response rates and overall survival in HER2-positive gastric and gastroesophageal junction tumors after trastuzumab-based therapy. This supports its role as an important second-line or later treatment option. The ongoing advancement of ADCs targeting CLDN18.2, TROP2, and CEACAM5 indicates that this therapeutic category will continue to expand across gastrointestinal neoplasms. Nonetheless, these advancements are accompanied by a specific and clinically significant toxicity profile. Hematologic suppression, gastrointestinal side effects, hepatotoxicity, and notably interstitial lung disease (ILD) are essential consequences that may need inpatient assessment and care. Interstitial lung disease (ILD), although uncommon, may be severe or lethal if not identified immediately and treated swiftly with medication cessation and corticosteroids. In hospitalized patients, distinguishing ADC-related toxicity from infection or disease progression is often difficult owing to overlapping clinical manifestations, requiring meticulous evaluation and interdisciplinary cooperation. As ADCs are integrated into earlier treatment lines and across a broader patient population, hospital systems must evolve to ensure prompt identification, consistent management protocols, and efficient collaboration between oncology and inpatient teams. This study analyzes the mechanisms, clinical effectiveness, and safety profile of ADCs in gastrointestinal oncology, pointing out the importance of institutional preparedness to safely incorporate these medicines into standard clinical practice. These features also align ADC therapy with personalized medicine by emphasizing biomarker-guided patient selection and individualized toxicity monitoring.
BSO-AD: An Ontology for Representing and Harmonizing Behavioral Social Knowledge in ADRD
Li, Haifang , Yu, Yue, Bhandarkar, Avanti , Kumar, Rakesh, Clark, Isaac Heath, Hu, Yutong , Cao, Weiguo, Zhao, Na, LI, FANG, Tao, Cui, Tao, Cui , Li, Fang , Clark, Isaac H, Li, Fang , Tao, Cui , Cao, Weiguo

Mayo Clinic

No container title available | April 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.30.26349756 | PMID 41959815 Get It

ABSTRACT Behavioral and social factors (BSFs) substantially influence the risk, onset, and progression of Alzheimer’s disease and related dementias (ADRD), yet BSF-related knowledge remains scattered across heterogeneous sources, posing critical challenges for data harmonization and evidence synthesis. To address this gap, we present the B ehavioral S ocial Data and Knowledge O ntology for AD RD (BSO-AD), a FAIR-compliant semantic resource for representing and harmonizing BSFs and ADRD-related knowledge. BSO-AD was developed following established ontology design principles with reuse of existing ontologies and controlled terminologies, including the Social Determinants of Health Ontology, Drug Repurposing-Oriented Alzheimer’s Disease Ontology, AD-Onto, ICD-9-CM, and ICD-10-CM. Relationships between BSFs and ADRD were derived through literature mining. BSO-AD contains 1,690 classes, 152 object properties, 49 data properties, and 40 annotation properties. Ontology evaluation through Hootation-based domain expert review and a scalable LLM-assisted ontology assessment framework demonstrated high domain coverage and strong semantic coherence. BSO-AD provides a semantic foundation for data harmonization and knowledge integration in BSF-related ADRD research, while the LLM-assisted evaluation framework supports scalable and automated ontology assessment.
Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms
Haugk, Beate , White, Steven, Marchegiani, Giovanni, Holmberg, Marcus, Zerbi, Alessandro, Lu, Zipeng , Inoue, Y., Choi, Munseok , Kang, Chang Moo, Visser, B., Corpelijn, Lieke, Andersson, Bodil, Bereza-Carlson, Paulina, Björnsson, Bergthor, Wennerblom, Johanna, Goh, Brian K. P., Hartman, V., Ahmad, Syed, Patel, Sameer, Berrevoet, Frederik, Mortensen, Kim Erlend, Roberts, K., Lynch, Calum, Gupta, Amit, Kleeff, Joerg, Addeo, Pietro, Friess, Helmut, Koea, Jonathan, Gomez, Dhanny , Gordon-Weeks, Alex, Doria, Cataldo, Tzimas, Georgios, Franklin, O., Månsson, C., Cabús, Santiago Sánchez, Bhogal, Ricky H. , Pathak, Samir, Honselmann, Kim Christin, Balakrishnan, Anita, Mann, Kulbir , Gill, Anthony J., Mittal, A, Samra, Jas, Athwal, Tejinderjit, Loveday, Benjamin, Bhardwaj, Neil, Menon, Krishna, Thapa, Prabin, Matsumoto, Ippei, Jamieson, Nigel, Rebours, Vinciane, Descourvières, Clémence, Davidson, BR, Soreide, Kjetil, Pandanaboyana, Sanjay, Collaborative, Adeno-IPMN2, Kumar, Ajit, González, Carol Natalia Clavijo, Lam, Shi, L’Official-German, Ivan, Bergner, Tina, Rosso, Edoardo , Giulianotti, Pier Cristoforo , Morreau, Mathew , Dili, Alexandra, Sotiropoulou, Maria , Kuzman, Matta , Büyükkasap, Ahmet Çağrı, Uludağ, Gökhan, McGuigan, Mari-Claire , Chouari, Tarak , Dogul, Ahmet, Doğu, Doğukan , Rebelo, Artur, Holewik, Franziska Bernadette, Plesa-Furda, Roxana, Revoredo, Fernando, Galanis, Ilias , Maharjan, Dhiresh, Ghorbani, Poya , Lind, Max, Ami, Katsuya , Vijayashanker, Aarathi , Alsaoudi, Tareq , Lundgren, Linda , Ellisa, Katrina, Hong, Paul , Gupta, Archit, MartinXu, Congde, Konstantoudakis, Georgios, Christophides, Thalis, Spurring, Eleanor Margaret, Iwao, Yasuhito, Pirklc, Martin, Vaitha, Ruhi , Tiwari, Navneet, Sheel, Andrea, Kotecha, Krishna , Stavrou, Gregor A., Patel, Rikhilroy, Misca, Mihaela , Hammond, John, Roalso, Marcus Thomas Thor, Soomro, Faiza H, Halimi, Asif , Kendall, Timothy, Patel, Visad, Stankic, Dunja, Dries, Pieter , Hein, Charlotte, Betram, Julia, Jacob, Rosetta, Wilson, Gregory, Redas, Souheil, Poškus, Augustas, Mosert, Paula Lucia, Šilinskaitė, Ugnė , Hirose, Yuki, Liu, Xue, Standaert, Lars, Kay, Tegan J, Nishida, Kenji, Peddakota, Vivek , Gupta, Amit , Kang, Chang Moo , Ven Fong, Zhi, Kang, Chang Moo , Lucocq, James E. , Marchegiani, Giovanni , Zerbi, Alessandro , Pagnanelli, Michele , Visser, B. , Andersson, Bodil , Bereza‐Carlson, Paulina , Björnsson, Bergþór , Wennerblom, Johanna Hansson , Labori, Knut Jørgen , Goh, Brian K P , Hartman, Vera , Berrevoet, Frederik Christiaan , Ausania, Fabio , Bertrand, Claude , Kleeff, Joerg, Addeo, Pietro , Bellotti, Ruben , Fong, Zhi Ven , Friess, Helmut , Koea, Jonathan , Gordon-Weeks, Alex Nicolas , Doria, Cataldo , Franklin, Oskar , Pathak, Samir , Honselmann, Kim C. , Balakrishnan, Anita , Harrison, Ewen M. , Gill, A J, Mittal, Anubhav, Samra, Jas , Athwal, Tejinderjit , Loveday, Benjamin P. T. , Teh, Catherine , Bhardwaj, Neil , Menon, Krishna, Matsumoto, Ippei , Jamieson, Nigel , Rebours, Vinciane , Søreide, Kjetil , Martlı, Hüseyin Fahri , Roeyen, Geert , Antonakis, Pantelis T. , Bramis, Konstantinos , Hall, Lewis A , Valle, Valentina , Connor, Saxon J. , Kapiris, Stylianos A. , Kerem, Mustafa , Rebelo, Artur , Plesa-Furda, R., Filho, Omero Pereira da Costa , Galanis, Ilias, Konstantoudakis, Georgios, Christophides, Thalis, McGuinness, Matthew James , Yaqub, Sheraz , Pellegrini, Riccardo , Perri, Giampaolo , Sheel, Andrea , Sheen, Amy , Evans, Daisy, Ghamarnejad, Omid , Karavias, Dimitrios D. , Roalsø, Marcus T. T. , Stankic, Dunja , Grubor, Nikica , Gulla, Aistė , Furukawa, Takaaki , Hirose, Yuki , Yin, Lingdi , Inoue, Yosuke

Mayo Clinic

JAMA Network Open | March 27, 2026 | Volume: 9 | Issue: 3 | Pages: e263688

10.1001/jamanetworkopen.2026.3688 | PMID 41893840 Get It

Importance Adjuvant chemotherapy regimens may be administered after pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMNs), although the evidence supporting their use is limited. Objective To evaluate the survival benefit associated with contemporary adjuvant chemotherapy regimens after resection in A-IPMNs between 2017 and 2023. Design, Setting, and Participants This retrospective cohort study was an international, multicenter study with 69 participating centers across Europe, North America, South America, and the Asia-Pacific region. Patients undergoing resection for A-IPMNs were included. Data were analyzed from May to August 2025. Intervention Contemporary adjuvant chemotherapy regimens, such as gemcitabine-capecitabine (GemCap); 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX), modified FOLFIRINOX (mFOLFIRINOX), and S-1. Main Outcome and Measure Overall survival (months). Results Among 1321 patients (median [IQR] age 70 [63 to 76] years; 713 males [54.0%] and 608 females [46.0%]), 781 patients (59.1%) received adjuvant chemotherapy, while in 181 patients (13.7%) it was omitted due to poor patient fitness. Of patients who received adjuvant chemotherapy, 568 patients (72.6%) received contemporary regimens, including GemCap (232 patients [29.7%]), FOLFIRINOX (176 patients [22.5%]), mFOLFIRINOX (71 patients [9.1%]), and S-1 (70 patients [9.0%]). The median (IQR) follow-up for the cohort was 64.2 (40.4 to 85.0) months, and the median overall survival was 73.8 months (95% CI, 66.4 to 81.9 months). After 90-day landmark analysis and exclusion of patients ineligible for chemotherapy, adjuvant chemotherapy vs no adjuvant chemotherapy (propensity score–matched populations, 243:243 patients) was not associated with improved overall survival (median, 82.3 months; 95% CI, 78.2 months to not applicable [NA] vs not reached; 95% CI, 75.3 months to NA; P = .58). Contemporary regimens vs no adjuvant chemotherapy (propensity score–matched populations, 309:309 patients) was not associated with longer survival, and a mean survival benefit greater than 4.2 months over 5 years was excluded (difference in restricted mean survival, 1.26 months; 95%, −1.72 to 4.24 months). Treatment outcomes did not vary by chemotherapy regimen or disease characteristic (eg, N stage or carbohydrate antigen 19-9 level). Conclusions and Relevance In this study, contemporary adjuvant chemotherapy was not associated with improved overall survival in A-IPMNs, and a randomized clinical trial is indicated.
Population‐Based Epidemiology of Autoimmune Seizures and Epilepsies
Thakolwiboon, Smathorn , Wood, Kathryne N., Paramasivan, Naveen, Smith, Kelsey M., Dasari, Surendra, Devine, Michelle F., McKeon, Andrew , Ζεκερίδου, Αναστασία , Flanagan, Eoin P., Pittock, Sean J., Dubey, Divyanshu , Stabile, Andrea , McKeon, Andrew , Zekeridou, Anastasia , Dubey, Divyanshu , Thakolwiboon, Smathorn , Paramasivan, Naveen Kumar , Britton, Jeffrey W. , Smith, Kelsey M. , DASARI, SURENDRA, Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

Annals of Neurology | March 25, 2026 | Volume: 100 | Issue: 1 | Pages: 74-83

10.1002/ana.78204 | PMID 41876839 Get It

Objective To estimate the prevalence, incidence, and disease burden of autoimmune seizures and epilepsies in Olmsted County. Methods We conducted a retrospective, population‐based study using the Rochester Epidemiology Project (1996–2019). Age‐ and sex‐standardized rates (2019 United States standard population) per 100,000 were calculated with 95% confidence intervals (95% CIs). Temporal trends in incidence were assessed over 3 consecutive 8‐year intervals (1996–2003, 2004–2011, and 2012–2019) using Poisson regression to estimate rate ratios per period and trend. Disability‐adjusted life years (DALYs), years of life lost (YLL), and years lived with disability (YLD) and 95% uncertainty intervals (95% UIs) were estimated for 2019. Results Twenty‐three patients were identified between 1996 and 2019. In 2019, the standardized prevalence of all autoimmune seizures and epilepsies was 9.81 (95% CI, 5.59–15.21) per 100,000, including autoimmune‐associated epilepsy (AAE) 7.27 (3.74–11.95) and acute symptomatic seizures secondary to autoimmune encephalitis (ASSAE) 2.55 (0.69–5.60). From 1996 to 2019, the standardized incidence was 0.50 (0.29–0.77) per 100,000 person‐years overall, with AAE 0.36 (0.19–0.59) and ASSAE 0.15 (0.05–0.30). By period, the standardized incidence of all autoimmune seizures and epilepsies suggested a rising trend from 0.28 (95% CI, 0.06–0.68) in 1996 to 2003 to 0.60 (95% CI, 0.24–1.12) in 2004–2011, then plateaued at 0.53 (95% CI, 0.21–1.00) in 2012 to 2019 (rate ratio per 8‐year interval 1.30, 95% CI, 0.71–2.38), largely driven by the seropositive subgroup. The standardized DALY rate was 26.27 (95% Uncertainly intervals [UI], 5.30–67.09) per 100,000 (YLL 20.07 [0.00–60.21] and YLD 6.20 [5.06–7.39]). Interpretation Although autoimmune seizures and epilepsies remain rare, they result in a disproportionately high disease burden. ANN NEUROL 2026;100:74–83
140: PROGNOSTIC VALUE OF BODY COMPOSITION IN HEART TRANSPLANT RECIPIENTS: A REVIEW AND META-ANALYSIS
Merchant, Kiran, Antar, Mohamed, Ferreira, Esteban Rodriguez, Jena, Anek , Sarangi, Swapna , Banker, Himanshi , Ghosh, Saptarshi, Rios, Anthony Navarrete, Singh, Aditya, Shah, Syed Hamza, Bordini, Joao, Kumar, Uroosa

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001182556.15437.19 Get It

138: RENAL PROTECTION WITH AMINO ACID INFUSION AFTER CARDIAC SURGERY: REVIEW AND META-ANALYSIS OF RCTS
Jena, Anek , Singh, Aditya , Merchant, Kiran, Antar, Mohamed, Ferreira, Esteban Rodriguez, Rios, Anthony Navarrete, Banker, Himanshi , Sarangi, Swapna , Shah, Syed Hamza, Kumar, Uroosa, Ghosh, Saptarshi

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001182548.24051.da Get It

Interrogation of glioma immune microenvironment identifies a non-canonical role for microglial Galectin-9 in tumor cell adhesion and phagocytosis
Gupta, Pravesh , Valdebenito-Silva, Silvana, Chakrapani, Prashanth, Oberai, Shivangi , Katayama, Hiroshi , Wang, Linghua, Eugenin, Eliseo A., Bhat, Krishna P., Kumar, Gayatri, Valdebenito, Silvana , Kumar, Gayatri , Dang, Minghao , Eugenín, Eliseo A. , Bhat, Krishna

Mayo Clinic

Frontiers in Immunology | March 24, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1733688 | PMID 41953006 Get It

Glioma-associated microglia/macrophages (GAMs) have traditionally been described as immunosuppressive. However, within their highly heterogeneous repertoire, pro-phagocytic and cytotoxic subsets with anti-tumoral properties exist. Although macrophages (MACs) can exhibit tumor-suppressive functions, their anti-glioma properties largely remain elusive. To identify anti-glioma myeloid cell effectors, we performed directionally concatenated ligand-receptor (L-R) interactome analyses from dendritic cells (DCs) and microglia (MG) to lymphoid (CD4 + T, Tregs, CD8 + T, NK, and NKT) cells identified by our recent single-cell transcriptomics interrogation of tumor-associated CD45 + leukocytes from tumor brains of eighteen isocitrate dehydrogenase (IDH)–stratified glioma patients. Within DC-specific and MG-specific interactomes, we identified LGALS9 , which encodes Galectin-9, as a key mediator of cell–cell interactions in IDH-wild type (IDH-wt) gliomas. Spectral cytometry, immunohistochemistry, and Western blotting analyses confirmed the abundant expression of Galectin-9 in glioma-associated MG, but not in tumor cells. Furthermore, differential gene enrichment analyses revealed transcripts associated with cellular adhesion (coronin 1A, integrin) and phagocytosis (FcγR, phospholipase D, Rab family proteins, etc.) pathways that were significantly upregulated in Galectin-9 + compared to Galectin-9 − MG and MACs. Using an ex-vivo primary human microglia (pMG) and patient-derived glioma stem cells (GSCs) co-culture system, we evaluated the functional role of Galectin-9. Confocal imaging analyses of co-cultured pMG with GSCs revealed that siRNA-mediated knockdown or antibody-based neutralization of Galectin-9 significantly impaired pMG–GSC adhesion. In addition to reduced adhesion, phagocytosis of GSCs was dramatically attenuated across all Galectin-9 silenced or neutralized pMG. Altogether, our study underscores the unappreciated non-canonical role of Galectin-9 in MG as a regulator of glioma cell adhesion and phagocytosis that can be harnessed for glioblastoma immunotherapy.
Circulating levels of insulin‐like growth factor I ( IGF ‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study
Benavente, Yolanda, Hermosa, Sara, Clay‐Gilmour, Alyssa, Brown, Elizabeth , Hofmann, Jonathan N., Rothman, Nathaniel, Lan, Qing, Berndt, Sonja I., Albanes, Demetrius, Purdue, Mark, Chanock, Stephen J., Norman, Aaron, Kumar, Shaji K., Vachon, C M, Novak, Anne J. , Ghesquieres, Herve, Bracci, Paige M., Holly, Elizabeth, Griffin, Rosalie G., Vermeulen, Roel , Hjalgrim, Henrik, Smedby, Karin Ekström, Cheah, Simon , Monnereau, Alain, Arslan, Alan, Zhang, Yawei, Camp, Nicola J., Sborov, Douglas W., Ziv, Elad , Joseph, Vijai, Teras, Lauren R., Patel, Alpa V. , Vajdic, Claire M., Cocco, Pierluigi, Alemany, Laia, McKay, James, Casabonne, Delphine , Monnereau, Alain , Brown, Elizabeth E , Machiela, Mitchell J , Slager, Susan L , Cerhan, James R , Rajkumar, S Vincent , Novak, Anne J , Habermann, Thomas , Salles, Gilles A , Hildebrandt, Michelle A T , Jayasekara, Harindra , Cheah, Simon , Kane, Eleanor , Guilloteau, Adrien , Casabonne, Delphine , Ziv, Elad , Benavente, Yolanda , Papadimitriou, Nikos , Clay‐Gilmour, Alyssa , Hofmann, Jonathan N. , Rothman, Nathaniel , Lan, Qing , Berndt, Sonja I. , Albanes, Demetrius , Machiela, Mitchell J. , Chanock, Stephen Jacob , Bhatti, Parveen , Cozen, Wendy , Slager, Susan L. , Cerhan, James R. , Rajkumar, S. Vincent , Habermann, Thomas M. , Link, Brian K. , Salles, Gilles , Ghesquières, Hervé , Bracci, Paige M. , Waller, Rosalie G. , Hildebrandt, Michelle A.T. , Kolijn, Pieter Martijn , Hjalgrim, Henrik , Jayasekara, Harindra , Chen, Yu , Camp, Nicola J. , Sborov, Douglas W. , Osman, Afaf E.G. , Vivo, Immaculata De , Teras, Lauren R. , Kane, Eleanor , Vajdic, Claire M. , Alemany, Laia, Sáinz, Juan , McKay, James, Birmann, Brenda M.

Mayo Clinic

British Journal of Haematology | March 24, 2026 | Volume: 208 | Issue: 6 | Pages: 1942-1953

10.1111/bjh.70444 | PMID 41873017 Get It

Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants ( n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified genetic variants associated with circulating total IGF‐I and IGF‐binding protein 3 (IGFBP‐3) in the InterLymph consortium (2434 MM and their 2567 controls). Finally, additional lymphoid neoplasm (LN) subtypes were included for comparison with the main hypothesis. Circulating IGF‐I level was positively associated with MM risk Hazard ratio‐HR‐per one standard deviation‐SD‐increase (HR 1‐SD = 1.11, 95% confidence interval [CI]: 1.01–1.22; p ‐value = 0.03), especially closer to diagnosis. Genetically inferred IGF‐I levels were associated with increased MM risk (odds ratio [OR] = 1.27, 95% CI: 1.05–1.54) but not with any other LNs. Genetically inferred IGFBP‐3 levels showed no associations with any LN evaluated. Corroborating previous findings, in a secondary analysis, IGF‐I levels were associated with the risk of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in males with higher body mass index (HR 1‐SD in obese male = 1.36, 95% CI: 1.14–1.61). Our serological and MR analyses suggest a contributing role of IGF‐I in the susceptibility of MM; the CLL/SLL findings warrant further investigation considering sex‐specific adiposity.